Snibe Diagnostic
The main business of Shenzhen Snibe Diagnostics is to develop
The main business of Shenzhen Snibe Diagnostics is to develop, produce and sell series of automatic chemiluminescence immunoassay instruments and supporting reagents, and is the leader in this field in China. The company's products are mainly used to provide diagnostic information for disease prevention, diagnosis, treatment monitoring, prognosis observation, health status evaluation and hereditary disease prediction.
Innovative Drug Developer Rezu Bio Raised CNY 10 Mn in Series Pre-A
ForLong Biotech Nets Over CNY 100 Mn in Series A
CytoCan Corp. Nets CNY 10 Mn in Seed Round
Levostar Completes Pre-A Financing Round to Further Invest in CGT
BlissBio Nets Over CNY 100 Mn in Series B+
Weiyou Gene Nets Tens of Millions of CNY in Series Pre-A Round
NaviSeed Nets Tens of millions of CNY in Angel Round
Nuwacell Nets Hundreds of Mns of CNY in Series A
Enitiatebio Nets One Hundred Million of CNY in Series A Round
And platinum medicine b7h4x4-1bb bispecific antibody were approved by FDA for new drug research
Fosun pharma and Amgen have reached cooperation to accelerate the commercialization of two innovative drugs in China
HastenPharma Secures USD 315 Mn in Financing to Focus on M&A Business and R&D
Anhui-based biopharmaceutical company HastenPharma(海森生物) raised USD 315 million in funding on April 20, with the financing round aimed at focusing on future mergers and acquisitions and product innovation, according to EqualOcean.
Apr 23, 2023 12:20 PM
It is expected to achieve functional cure of chronic hepatitis B! GSK antisense therapy phase IIB positive clinical results
Aibo biology: cooperate with Jiahe biology to jointly develop tumor mRNA drugs
F-star to be acquired by China biopharmaceutical with USD 161million
New industrial biology: obtaining medical device registration certificate